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OBJECTIVE — Continuous glucose monitoring (CGM) has been found to improve glucose
control in type 1 diabetic patients. We estimated the cost-effectiveness of CGM versus standard
glucose monitoring in type 1 diabetes.
RESEARCH DESIGN AND METHODS — This societal cost-effectiveness analysis
(CEA) was conducted in trial populations in which CGM has produced a signiﬁcant glycemic
beneﬁt(A1C7.0%inacohortofadultsaged25yearsandA1C7.0%inacohortofallages).
Trial data were integrated into a simulation model of type 1 diabetes complications. The main
outcome was the cost per quality-adjusted life-year (QALY) gained.
RESULTS — Duringthetrials,CGMpatientsexperiencedanimmediatequality-of-lifebeneﬁt
(A1C 7.0% cohort: 0.70 quality-adjusted life-weeks [QALWs], P  0.49; A1C 7.0% cohort:
1.39 QALWs, P  0.04) and improved glucose control. In the long-term, CEA for the A1C
7.0% cohort, CGM was projected to reduce the lifetime probability of microvascular compli-
cations;theaveragegaininQALYswas0.60.Theincrementalcost-effectivenessratio(ICER)was
$98,679/QALY (95% CI 60,000 [fourth quadrant] to 87,000 [second quadrant]). For the
A1C7.0%cohort,theaveragegaininQALYswas1.11.TheICERwas$78,943/QALY(15,000
[ﬁrst quadrant] to 291,000 [second quadrant]). If the beneﬁt of CGM had been limited to the
long-term effects of improved glucose control, the ICER would exceed $700,000/QALY. If test
strip use had been two per day with CGM long term the ICER for CGM would improve
signiﬁcantly.
CONCLUSIONS — Long-termprojectionsindicatethatCGMiscost-effectiveamongtype1
diabeticpatientsatthe$100,000/QALYthreshold,althoughconsiderableuncertaintysurrounds
these estimates.
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T
he Diabetes Control and Complica-
tion Trial (DCCT) established the
clinical beneﬁts of intensive glucose
control in type 1 diabetes (1). Despite the
availabilityofinsulinpumpsandinsulinan-
alogues, achieving optimal glucose control,
while avoiding hypoglycemia, continues to
be a signiﬁcant challenge for patients.
An important component of glucose
control is glucose monitoring. Conven-
tional self-glucose monitoring permits
patients to periodically measure capillary
glucose. This leaves patients unaware of
postprandial hyperglycemia and asymp-
tomatic nocturnal hypoglycemia (2).
Newer continuous glucose monitoring
(CGM) technology, which measures glu-
coselevelsinsubcutaneoustissue,hasthe
potential to overcome these challenges
and increase the likelihood that patients
with diabetes can achieve and maintain
optimal glucose control without symp-
tomatic hypoglycemia. While there are
potential advantages of CGM, the tech-
nologydoeshavesomedisadvantages,in-
cluding discomfort from the probe,
ongoing use of conventional monitoring,
potential overestimation of the frequency
of overnight low glucose levels, and high
costs (3).
Recently, parallel multicenter trials
comparing CGM with conventional self-
glucose monitoring alone were con-
ductedinpatientswithA1C7.0%(A1C
7.0% cohort) and in patients with A1C
7.0% (A1C 7.0% cohort) (4). In the
A1C 7.0% cohort, CGM was found to
signiﬁcantly reduce average A1C levels
(0.53 [95% CI 0.71 to 0.35], P 
0.001) in adults (aged 25 years) (5). In
the A1C 7.0% cohort, CGM helped in-
tervention patients maintain their A1C at
6.5%, while control patients experienced
an increase in A1C of 0.3% (6). The pur-
pose of this study is to evaluate the cost-
effectiveness of CGM technology
compared with standard glucose moni-
toring in the type 1 diabetic patients from
the societal perspective.
RESEARCH DESIGN AND
METHODS— The design of the Juve-
nile Diabetes Research Foundation
(JDRF)-CGM trials has been previously
described (4–6). In brief, patients with
type 1 diabetes were randomized to CGM
versus standard glucose monitoring for 6
months. In the A1C 7.0% study cohort,
subjects were stratiﬁed into three pre-
speciﬁed age-groups (8–14, 15–24, and
25 years). The A1C 7.0% cohort was
not stratiﬁed by age. We conducted cost-
utility analyses (CUAs) in the adult (aged
25 years) A1C 7.0% cohort and the
overall A1C 7.0% cohort. For the re-
mainder of this manuscript, the adult
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the A1C 7.0% cohort.
CUA data collected during trials
Costs and direct-cost items. The pri-
mary costs of interest for this CUA are the
costs of CGM technology and training.
During the trial, investigative staff re-
portedontimespentwithpatientsduring
scheduledandnonscheduledencounters.
We included staff time devoted to CGM
training and diabetes management and
excluded research time. The utilization of
CGM was routinely collected as days of
useperweek.Theuseofstandardglucose
monitoring was recorded as number of
tests per day.
Adult patients and caregivers of chil-
dren were surveyed at baseline and 6
months regarding health service utiliza-
tion outside of the trial. Survey data in-
cluded items for routine ofﬁce visits,
after-hours clinic visits, emergency room
visits, 911 calls, and hospitalizations.
Indirect-cost items. Apart from health
service utilization, adult patients and
caregivers of children were surveyed at
baseline and 6 months on the number of
hours devoted to diabetes care per day,
number of days missed from work or
school due to diabetes, and number of
days of work underperformance.
Unit costs. The unit costs and their
sources are listed in online appendix Table
1 (available at http://care.diabetesjournals.
org/cgi/content/full/dc09–2042/DC1). The
daily cost of CGM technology was calcu-
lated based on Food and Drug Adminis-
tration–recommended frequency of sensor
replacement and the expected frequency
of receiver and transmitter replacement.
The costs of the three devices (DexCom,
Medtronic, and Abbott) used during the
trial were averaged to arrive at a daily cost
of CGM of $13.85 in year 1 (online ap-
pendixTable2).ThecostsofCGMequip-
ment reﬂect full retail prices, with no
insurer discounts. This daily cost was
multiplied by the reported weekly use of
CGM to arrive at an overall cost of CGM
technology (e.g., 6 days of use/week  an
annual cost of $4,335).
Measurement of quality-of-life
effects
The quality-of-life effects of CGM were
expected to manifest themselves in terms
of immediate changes in quality of life
from using the device as well as from the
occurrence of long-term complications of
diabetes that might be altered by changes
in glycemic control. We collected utilities
from trial patients for both immediate
(experienced) quality-of-life effects of
CGM and for the quality-of-life effects of
potential long-term complications (7).
We collected experienced utility data
by using the Health Utility Index (8) and
by eliciting time tradeoff (TTO) utilities
for overall experience (7). In the TTO
method, patients were asked to consider
theircurrentstateofhealthincomparison
to life in perfect health. Experienced util-
ities were elicited at baseline, 13 weeks,
and 26 weeks. For children aged 18
years, parents served as surrogates in re-
sponding to questionnaires. A priori, we
planned to use the TTO utilities as the
most theoretically grounded measure for
the CUA.
For complication utilities, we used
the TTO method to elicit utilities for life
with blindness, end-stage renal disease
(ESRD), lower-extremity amputation,
chronic angina, and stroke (7). Parents of
children aged 18 years served as surro-
gates for their children during complica-
tion utility elicitation. For the CUA, we
used the same set of overall population
complication utility weights for both trial
arms in long-term projections.
Calculation of the incremental
cost-effectiveness ratio
Within-trial analyses. Experienced
utilitiesatbaseline,week13,andweek26
were modeled using a random-effects lin-
ear model (9,10). In the regression, we
adjustedfortreatmentarmindicator,time
indicators for 13 and 26 weeks, interac-
tion between time and treatment indica-
tors, and a variety of subject-level
confounders. Quality-of-life predictions
were obtained at weeks 13 and 26 for all
subjects (in both control and CGM arms)
asiftheybelongedtoeithertrialarm.This
was necessary to account for the differ-
enceinbaselinequalityoflifeacrosstreat-
ment arms and was accomplished by the
method of recycled predictions, where
thetreatmentindicatoranditsinteraction
with time were turned on and off subse-
quently. The total quality-adjusted life
weeks (QALWs) were calculated as the
area under the quality-of-life time trends
under each arm. Total direct and indirect
costs over the 6-month period were ana-
lyzed separately using generalized linear
modelswithlog-linkandvariances.SEs
for both costs and effects were obtained
simultaneously using 500 bootstrap rep-
licatesthatwereclusteredbysubjects.Es-
timates of costs and effects and their
empirical distributions were used to cal-
culate the overall incremental cost-
effectiveness ratios and their 95% CIs.
Lifetimeanalyses. Forthelifetimeanal-
yses, we extrapolated the ﬁndings from
the clinical trials over the projected life-
timeofpatients.Fortheselifetimeprojec-
tions,wedevelopedaMonteCarlo–based
Markov simulation model that uses
framework and data inputs shared by
prior cost-effectiveness analyses of treat-
ments in type 1 diabetes (online technical
appendix) (11). The model is framed by
the simultaneous progression of disease
through major categories of complica-
tions and their associated Markov states
(online appendix Fig. 1) (Microsoft Excel
2000, Microsoft, Seattle, WA; and @Risk
4.0 for Windows, Palisades, Newﬁeld,
NY).Afterassignmentofcharacteristicsof
hypothetical subjects, the model simu-
lates the natural history of diabetes based
on these characteristics.
A detailed description of the model
inputs is available in online appendix Ta-
ble 3. For all microvascular complica-
tions, we used the original DCCT
prediction models for intermediate com-
plications that relate A1C with the cumu-
lative probability of developing these
intermediate complications (courtesy of
Richard Eastman) (12). For the transi-
tions from intermediate to end-stage mi-
crovascular complications, we used
annual probabilities found in the litera-
ture (13–15).
For cardiovascular complications,
there were no published prediction mod-
els for patients with type 1 diabetes at the
time of our analysis. In lieu of such mod-
els, we used prediction models for type 2
diabetic patients for ischemic heart dis-
ease, myocardial infarction, congestive
heartfailure,andstroke(16).Tocalculate
cardiovascularrisk,weusedage-andsex-
stratiﬁed risk factor data from the study
population whenever possible. For blood
pressure and cholesterol inputs, we used
data for the nondiabetic population from
the National Health and Nutrition Exam-
ination Surveys. Observational studies
have found that type 1 diabetic patients
typically have blood pressure and choles-
terol levels that are closer to the nondia-
betic population than the type 2 diabetic
population (17). For mortality related to
diabetes complications, we used mortal-
ity prediction models developed with
type 2 diabetes data (16). To calculate
background mortality rates, we used Na-
tional Vital Statistics Life Tables (18).
For the lifetime analysis, the main
outcome of interest was the incremental
Cost-effectiveness of CGM
1270 DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 care.diabetesjournals.orgcost-effectiveness ratio (ICER) using an
intention-to-treat analysis (dollars/
QALYs). Unlike the within-trial analyses,
the lifetime analysis accounted for life-
time costs and beneﬁts with the assis-
tance of the simulation model. We
assumed a lifetime use of the CGM by
patients in the CGM trial and no adop-
tion by the control arm.
Projected CGM effects
Fromtheclinicaltrial,weknowthatCGM
had an impact on glucose levels as well as
on immediate, experienced utility. Both
effects were incorporated into lifetime
simulations. For the impact of CGM on
glucose levels, we evaluated CGM’s effect
asachangeinthedistributionofA1Clev-
els at 26 weeks and carried this difference
in distribution over the remaining life-
time. For the impact of CGM on experi-
enced utility, we evaluated CGM’s effect
as a change in the distribution of experi-
enced quality of life and carried this dif-
ferenceindistributionovertheremaining
lifetime. The assumption that both CGM
effects are maintained over time is based
on 12-month observational data that has
revealed that glycemic control, mean ex-
perienced utilities, and utilization of the
device were unchanged among CGM
patients.
Sensitivity analyses
To assess the relative contributions of im-
mediatequality-of-lifeandlong-termglu-
cose control beneﬁts, we ran analyses in
which the only beneﬁt was due to im-
proved glucose control. We also evalu-
ated the impact of variation in the daily
cost of CGM on the cost-effectiveness of
the technology. CGM use may eventually
lead to lower utilization of conventional
blood glucose monitors and associated
teststripuse.Toaccountforthispossibil-
ity, we conducted a sensitivity analysis
around the number of daily test strips
used among patients on CGM. We sepa-
rately evaluated the effect of future costs,
including medical costs for unrelated ill-
nesses, nonmedical costs, and future
earnings, on the overall cost-effectiveness
results (19).
Uncertainty
To express the degree of uncertainty
aroundICERs,wepresent95%CIs,using
thepercentilemethodbasedonbootstrap
replicates (20).
RESULTS— A description of the A1C
7.0% cohort and the A1C 7.0% co-
hort is provided in Table 1. The A1C
7.0% cohort had a mean baseline A1C
level of 7.5%, while the overall secondary
cohort had a mean A1C level of 6.3%.
Over 80% of patients in both cohorts
were insulin pump users.
Within-trial results
During the 6-month period of the trial,
CGM improved experienced quality of
life and increased costs in both cohorts
(Table 2). For the A1C 7.0% cohort,
Table 1—Baseline characteristics of the study populations
A1C 7.0% cohort A1C 7.0% cohort
Control CGM Control CGM
n 46 52 63 67
Female sex 26 (57) 31 (60) 33 (52) 36 (54)
Age (years) 44.69  12.35 41.23  11.21 31.84  17.63 29.38  16.29
Non-Hispanic white race 42 (91) 52 (100) 61 (97) 64 (96)
Duration of diabetes (years) 21.83  10 23.57  11 18.15  15 16.28  15
Daily insulin dose (units) 45.97  24 43.20  19 42.23  17 39.72  13
Pump users 39 (85) 43 (83) 50 (79) 62 (93)
A1C at baseline (%) 7.61  0.50 7.61  0.49 6.50  0.34 6.39  0.49
Daily home glucose meter
reading (times/day) 6.19  1.94 6.89  3.17 6.31  2.72 7.67  3.07
Data are means  SD or n (%). A1C 7.0% cohort is only for those aged 25 years. The only statistical difference between control and CGM patients was in the
proportion of pump users among the A1C 7.0% cohort (P  0.03).
Table 2—Within-trial results
A1C 7.0% cohort A1C 7.0% cohort
Control CGM Difference  SE Control CGM Difference  SE
QALWs 21.68  0.60 22.38  1.08 0.70  1.03 21.84  0.66 23.23  0.81 1.39  0.69*
Direct costs $3,984  242 $6,375  302 $2,391  376* $3,412  164 $6,529  277 $3,117  356*
Indirect costs $12,419  3,478 $15,979  4,100 $3,560  5,781 $17,352  4,338 $25,146  6,238 $7,794  7,097
Total costs $16,403  3,493 $22,354  4,127 $5,951  5,847 $20,764  4,351 $31,675  6,292 $10,991  7,163
ICER $/QALW
(95% CI) $8,501 (not deﬁned)
$7,849 (3,397 fourth quadrant, dominant to 66,829
ﬁrst quadrant)
ICER $/QALY
(95% CI) $442,052 (not deﬁned)
$408,148 (176,644 fourth quadrant, dominant to
3,475,108 ﬁrst quadrant)
DataaremeansSE,unlessotherwiseindicated.A1C7.0%cohortisonlyforthoseaged25years.Indirectcostsareestimatedfromreportsofsubjectandparent
hours devoted to diabetes care per day, number of days missed from work or school due to diabetes, and number of days of work underperformance. Dominant,
intervention improves health at a lower cost compared with control. Not deﬁned, there is so much uncertainty around the ICER that a 95% CI cannot be deﬁned.
*P  0.05.
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than control patients (means  SE)
(0.70  1.03 QALWs,P  0.49) that was
not statistically signiﬁcant. They also in-
curred higher direct medical ($2,391 
$376) and total costs ($5,951  $5,847).
The societal ICER for the within-trial pe-
riod was $8,501/QALW or $442,052/
QALY. There was considerable uncertainty
around the ICER, such that 95% CIs could
not be deﬁned.
For the A1C 7.0% cohort, CGM
patients had a signiﬁcantly higher qual-
ity of life during the trial (1.39  0.69
QALWs, P  0.04) compared with con-
trol patients. CGM patients also incurred
higher direct medical costs ($3,117 
$356) and total costs ($10,991 
$7,113). The societal ICER was $7,849/
QALW or $408,148/QALY. CIs for the
societal ICER ranged from dominant to
$213,000/QALY.
Long-term results
Base case analyses. In the lifetime anal-
ysis for both cohorts, CGM reduced the
expected lifetime incidence of intermedi-
ate and end-stage complications of type 1
diabetes while also increasing costs.
In the A1C 7.0% cohort, the model
predictedthattheuseofCGMwouldlead
to reductions in lifetime risk of blind-
ness (14.56312.00%), amputation
(10.5339.13%),andend-stagerenaldis-
ease (4.4132.37%). Life expectancy for
both intervention and control cohorts
was27years.Theaverageimprovement
in quality of life was 0.60 QALYs. The
ICER for the base case was $98,679/
QALY. The CIs for this ICER spanned
the southeast and northwest quadrants
of the cost-effectiveness plane (95% CI
60,007 [fourth quadrant, dominant] to
86,582 [second quadrant, domi-
nated]). The CIs reﬂect a large degree of
uncertainty about the ICER point
estimate.
For the A1C 7.0% cohort, the
model also predicted that CGM use
would lead to reductions in blind-
ness (16.19313.96%), amputation
(12.92311.73%), and end-stage renal
disease (2.4031.44%). Life expectancy
for both intervention and control cohorts
was37years.Theaverageimprovement
in quality of life was 1.11 QALYs. The
ICER for the base case was $78,943/
QALY. The CIs for this ICER spanned the
northeast and northwest quadrants of the
cost-effectiveness plane (95% CI 14,644
[ﬁrst quadrant] to 290,780 [second
quadrant, dominated]). The CIs for this
cohort were narrower than for the A1C
7.0% cohort but still reﬂect consider-
able uncertainty around the ICER.
Sensitivity analysis
If the beneﬁt of CGM was limited to glu-
cose lowering and subsequent complica-
tion prevention, CGM would not be
cost-effective by most conventional
thresholds.IntheA1C7.0%cohort,the
averagegaininQALYswouldbe0.08and
the ICER would be $701,397/QALY. In
the A1C 7.0% cohort, the average gain
in QALYs would be 0.07 and the ICER
wouldbe$1,185,384/QALY.Thebeneﬁts
from improved glycemic control are rela-
tively small due to the fact that complica-
tions are predicted to develop late in life,
and the beneﬁts of complication reduc-
tion are therefore heavily discounted.
We also performed sensitivity analy-
sesontheaveragedailycostofCGMhold-
ing utilization of the device constant
(online appendix Fig. 2). If the daily costs
of CGM were reduced from $13.85/day
($4,335/year) to $9.89/day ($3,096/year)
or below, the ICER would be below
$70,000/QALY for both study popula-
tions. In the test strip sensitivity analysis,
if test strip use among CGM patients was
two test strips per day as recommended
forcalibration,CGMwouldbecostsaving
compared with standard glucose moni-
toring. When accounting for future costs,
theICERsforthetwopopulationsdidnot
qualitatively change from the base case.
Table 3—Lifetime cost-effectiveness analysis results
Lifetime probability of:
A1C 7.0% cohort A1C 7.0% cohort
Control CGM Control CGM
Blindness 14.56 12.00 16.19 13.96
Neuropathy 34.96 30.56 33.46 30.41
Amputation 10.53 9.13 12.92 11.73
Microalbuminuria 19.30 13.15 12.43 9.46
End-stage renal failure 4.41 2.37 2.4 1.44
Myocardial infarction 11.53 11.24 11.24 11.04
Ischemic heart disease 10.41 10.22 10.82 10.66
Congestive heart failure 2.08 2.04 1.67 1.65
Stroke 1.94 1.92 1.84 1.81
Life expectancy (means) 26.79 26.84 36.54 36.58
Discounted QALYs (means) 13.75 14.35 16.69 17.80
Difference in QALYs 0.60 1.11
Discounted direct costs (means) $159,748 $217,882 $200,384 $285,149
Discounted indirect costs (means) $441,322 $441,955 $1,911,155 $1,913,776
Discounted total costs (means) $601,070 $659,837 $2,111,539 $2,198,925
Difference in total costs $58,767 $87,386
ICER means (95% CI) $98,679 (60,007 fourth
quadrant, dominant to 86,582
second quadrant, dominated)
$78,943 (14,644 ﬁrst quadrant to
290,780 second quadrant,
dominated)
Experiencedquality-of-lifebeneﬁtwasnotstatisticallysigniﬁcantduringthe6-monthtrialfortheA1C7.0%cohort.TheA1C7.0%cohortisonlyforthoseaged
25years.Dominant,interventionimproveshealthatalowercostcomparedwithcontrol;Dominated,interventionworsenshealthatincreasedcostcomparedwith
control.
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tinuous glucose monitors have been
foundtoimproveglycemiccontrolintype
1 diabetes in recent trials. In study popu-
lations where CGM improved glycemic
control, our within-trial analysis revealed
that CGM improved experienced quality
of life (signiﬁcant for the A1C 7.0% co-
hort and nonsigniﬁcant for the A1C
7.0% cohort) and increased costs.
Based on ICER point estimates, CGM was
notcost-effectivebyconventionalmetrics
during the ﬁrst 6 months of use of the
device, although there was considerable
uncertainty around these results.
When extrapolating beneﬁts in expe-
rienced quality of life and glycemic con-
trol over a lifetime, the ICER point
estimates from our analyses suggest that
CGM is a cost-effective technology, based
on the ICERs of commonly accepted dia-
betes therapies (21). Recent studies sug-
gest that the acceptable ICER threshold is
between $109,000 and $297,000/QALY,
above the commonly discussed $50,000/
QALY threshold (22). While the ICER
point estimates suggest that CGM is a
good value relative to the $109,000
threshold, the CIs were wide, reﬂecting
considerable uncertainty. For example,
for the A1C 7.0% cohort, the CIs in-
clude the possibility that CGM is domi-
nant (i.e., beneﬁcial and cost saving) but
also include the possibility that CGM is
dominated(i.e.,harmfulandcostincreas-
ing).MostoftheincrementalcostofCGM
is due to adding the CGM system ($4,335
in year 1), while maintaining conﬁrma-
torybloodglucosetesting.IfCGMwereto
leadtolessconﬁrmatorytesting,theICER
for CGM would improve dramatically.
One important insight from our anal-
ysis is that the overall quality-of-life effect
of CGM arises from its ability to both im-
prove the immediate quality of life of di-
abetic patients as well as reduce future
complications through enhanced glyce-
micmanagement.Theimmediatequality-
of-life effect of CGM was responsible for
the majority of projected lifetime beneﬁts
of the technology. For many patients,
CGM provides some of the ﬁrst insights
into their dynamic patterns of glucose
control. The provision of greater glucose
controldatamayhaveimprovedthequal-
ity of life of patients by facilitating deci-
sions related to food intake and insulin
regimens as well as by reducing the risks
and fears of hypoglycemia. These im-
provementsoccurredduringthe6-month
trial despite the fact that a large propor-
tionofpatientsenrolledinthesetrialshad
very high baseline quality of life (online
appendix Fig. 3).
The analysis of quality-of-life data
also suggests that the quality-of-life effect
of the CGM differed between the A1C
7.0%andA1C7.0%cohorts.Incom-
parison to the adult patients with subop-
timal glucose control, patients who were
already at optimal glucose control levels
achieved a signiﬁcant immediate quality-
of-life beneﬁt from CGM. This difference
couldhavebeenduetoalackofstatistical
power for the adult A1C 7.0% cohort
but may also have been due to a relatively
larger improvement in quality of life for
theA1C7.0%cohort.Theexactreasons
for the larger improvement in quality of
life for the A1C 7.0% cohort are not
entirely known. Quality of life of CGM
subjects may have improved due to a re-
duction in time spent with biochemical
hypoglycemia (median 54 vs. 91 min/
day),althoughthisdifferencewasnotsta-
tistically signiﬁcant (6). The difference in
experiences for these two trial cohorts
suggests that the effect of CGM may differ
across diabetic subpopulations, varying
bydiabetestype,baselineglucosecontrol,
and current therapy.
Our study has a number of important
limitations. Criticism could still be lev-
eled against our model choices. The
DCCT models of microvascular compli-
cations may not reﬂect the modern natu-
ral history of type 1 diabetes (23). For
cardiovascular complications, we relied
on type 2 diabetes cardiovascular models
due to a lack of type 1 diabetes cardiovas-
cularmodels(24).Despitethislimitation,
we found that the cardiovascular event
ratepredictedbyourmodelfortheDCCT
population was very similar to CVD rates
observed in the 20-year follow-up of
DCCT/Epidemiology of Diabetes Inter-
ventions and Complications Study (25).
Our model also does not account for the
potential impact of long-term reductions
inhypoglycemiathatmaybeproducedby
CGM. And ﬁnally, as mentioned earlier,
the patients in our cohorts had high base-
line utilities, measured by the TTO
method,whicheffectivelyplacedaceiling
on the magnitude of potential quality-of-
lifebeneﬁtthatcouldbebroughtaboutby
CGM.
Despite these limitations, this study
providessomeoftheﬁrstformalestimates
of the cost-effectiveness of CGM technol-
ogy. These estimates will require future
revision as the prices and functionality of
this technology evolves over time. The
limitations of the current study highlight
important areas of future research for the
economic evaluation of chronic disease
self-management technologies. The value
of such technologies depends in part on
their ability to improve the immediate
quality of life of patients. Commonly ac-
ceptedapproachestoquantifyingquality-
of-life effects are designed to measure
changes in traditional symptoms, such as
pain and daily functions such as walking.
These approaches may not accurately re-
ﬂectthesubtle,butimportant,effectsnew
devices have on addressing transient
symptoms, reducing anxiety and provid-
ing greater convenience for disease
management.Thisstudyalsoraisesfun-
damental questions about the approach
to assessing the economic value of a tech-
nology that may be highly valuable to pa-
tients willing to use the technology but
not to others.
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